C\u2019est un des m\u00e9dicaments sur lesquels Moderna concentre d\u00e9sormais ses efforts. Mercredi, le laboratoire am\u00e9ricain et son compatriote Merck ont annonc\u00e9 des r\u00e9sultats positifs pour leur vaccin exp\u00e9rimental \u00e0 ARN messager contre le cancer de la peau lors d\u2019un essai clinique de phase III, la derni\u00e8re \u00e9tape avant une commercialisation.<\/p>\n
D\u00e9nomm\u00e9 \u00abintism\u00e9ran autog\u00e8ne\u00bb, il s\u2019agit d\u2019une th\u00e9rapie \u00absur mesure\u00bb, con\u00e7ue \u00e0 partir des mutations sp\u00e9cifiques de la tumeur de chaque patient. Combin\u00e9e \u00e0 l\u2019immunoth\u00e9rapie Keytruda de Merck, cette mol\u00e9cule a permis d\u2019am\u00e9liorer de mani\u00e8re \u00abstatistiquement significative\u00bb la survie sans r\u00e9cidive chez des patients atteints d\u2019un m\u00e9lanome de stade avanc\u00e9 et pr\u00e9alablement op\u00e9r\u00e9s, par rapport \u00e0 un traitement au Keytruda seul, affirment les deux laboratoires, sans publier de chiffres. Ces donn\u00e9es doivent \u00eatre communiqu\u00e9es lors d\u2019un prochain congr\u00e8s m\u00e9dical international, pr\u00e9cise le communiqu\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"C\u2019est un des m\u00e9dicaments sur lesquels Moderna concentre d\u00e9sormais ses efforts. Mercredi, le laboratoire am\u00e9ricain et son compatriote…\n","protected":false},"author":2,"featured_media":267719,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4],"tags":[22,15582,44,967,21,174,23],"class_list":["post-267718","post","type-post","status-publish","format-standard","has-post-thumbnail","category-actualites","tag-actualites","tag-biotech","tag-economie","tag-finance","tag-news","tag-premium","tag-suisse"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch_fr\/117123424261277666","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/posts\/267718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/comments?post=267718"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/posts\/267718\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/media\/267719"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/media?parent=267718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/categories?post=267718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/tags?post=267718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}